Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes ...
Spruce Biosciences offers a high-risk, high-reward opportunity as it advances TA-ERT, potentially the first disease-modifying therapy for MPS IIIB, toward FDA approval. TA-ERT demonstrated durable ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results